Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 7.91 SEK 1.67% Market Closed
Market Cap: 1.9B SEK
Have any thoughts about
Vicore Pharma Holding AB?
Write Note

Vicore Pharma Holding AB
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vicore Pharma Holding AB
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Vicore Pharma Holding AB
STO:VICO
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Current Portion of Long-Term Debt
kr8.8m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Current Portion of Long-Term Debt
kr6.4m
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Current Portion of Long-Term Debt
kr152m
CAGR 3-Years
113%
CAGR 5-Years
61%
CAGR 10-Years
25%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Current Portion of Long-Term Debt
kr6.1B
CAGR 3-Years
42%
CAGR 5-Years
133%
CAGR 10-Years
123%
BioArctic AB
STO:BIOA B
Current Portion of Long-Term Debt
kr2.8m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vicore Pharma Holding AB
Glance View

Market Cap
1.9B SEK
Industry
Biotechnology

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

VICO Intrinsic Value
2.94 SEK
Overvaluation 63%
Intrinsic Value
Price

See Also

Back to Top